Literature DB >> 26970263

Anti-tubercular therapy for intraocular tuberculosis: A systematic review and meta-analysis.

Ae Ra Kee1, Julio J Gonzalez-Lopez2, Aws Al-Hity3, Bhaskar Gupta4, Cecilia S Lee5, Dinesh Visva Gunasekeran6, Nirmal Jayabalan7, Robert Grant8, Onn Min Kon9, Vishali Gupta10, Mark Westcott11, Carlos Pavesio11, Rupesh Agrawal12.   

Abstract

Intraocular tuberculosis remains a diagnostic and management conundrum for both ophthalmologists and pulmonologists. We analyze the efficacy and safety of anti-tubercular therapy (ATT) in patients with intraocular tuberculosis and factors associated with favorable outcome. Twenty-eight studies are included in this review, with a total of 1,917 patients. Nonrecurrence of inflammation was observed in pooled estimate of 84% of ATT-treated patients (95% CI 79-89). There was minimal difference in the outcome between patients treated with ATT alone (85% successful outcome; 95% CI 25-100) and those with concomitant systemic corticosteroid (82%; 95% CI 73-90). The use of ATT may be of benefit to patients with suspected intraocular tuberculosis; however, this conclusion is limited by the lack of control group analysis and standardized recruitment and treatment protocols. We propose further prospective studies to better establish the efficacy of ATT and ascertain the factors associated with favorable treatment outcomes.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  anti-tubercular therapy; intraocular; tuberculosis; uveitis

Mesh:

Substances:

Year:  2016        PMID: 26970263      PMCID: PMC5061337          DOI: 10.1016/j.survophthal.2016.03.001

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  77 in total

1.  Ocular tuberculosis: experience of an Italian and French cohort.

Authors:  Paolo Mora; Stella Ghirardini; Emmanuel Héron; Neila Sedira; Federico Olcelli; Stefano Gandolfi; José-Alain Sahel; Marie-Hélène Errera
Journal:  Acta Ophthalmol       Date:  2014-12-09       Impact factor: 3.761

Review 2.  Mechanisms of action of antimicrobials: focus on fluoroquinolones.

Authors:  D C Hooper
Journal:  Clin Infect Dis       Date:  2001-03-15       Impact factor: 9.079

3.  Intraocular tuberculosis.

Authors:  P H Rosen; D J Spalton; E M Graham
Journal:  Eye (Lond)       Date:  1990       Impact factor: 3.775

4.  Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.

Authors:  O Zimhony; J S Cox; J T Welch; C Vilchèze; W R Jacobs
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

5.  Role of the mantoux test and treatment with antitubercular therapy in a South Indian patient population of presumed intraocular tuberculosis.

Authors:  Kalpana Babu; Vidya Satish; Om Prakash; D K Subbakrishna; Krishna R Murthy
Journal:  Ocul Immunol Inflamm       Date:  2009 Sep-Oct       Impact factor: 3.070

6.  Tuberculous uveitis, a resurgent and underdiagnosed disease.

Authors:  Luca Cimino; Carl P Herbort; Raffaella Aldigeri; Carlo Salvarani; Luigi Boiardi
Journal:  Int Ophthalmol       Date:  2007-05-08       Impact factor: 2.031

Review 7.  Central nervous system tuberculosis: pathogenesis and clinical aspects.

Authors:  R Bryan Rock; Michael Olin; Cristina A Baker; Thomas W Molitor; Phillip K Peterson
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

8.  Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharat; R K Shandil; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

9.  Mycobacterial ocular inflammation: delay in diagnosis and other factors impacting morbidity.

Authors:  Sarju S Patel; Nehali V Saraiya; Howard H Tessler; Debra A Goldstein
Journal:  JAMA Ophthalmol       Date:  2013-06       Impact factor: 7.389

10.  Intravitreal moxifloxacin in the management of Ochrobactrum intermedium endophthalmitis due to metallic intraocular foreign body.

Authors:  David J Jacobs; Thomas J Grube; Harry W Flynn; Craig M Greven; Avinash Pathengay; Darlene Miller; Robert F Sanke; Joseph Thorman
Journal:  Clin Ophthalmol       Date:  2013-08-27
View more
  23 in total

1.  The clinical presentation and treatment outcomes of ocular tuberculosis: a 5-year experience in an endemic area.

Authors:  Jolly Tsui; Mary Ho; Grace Lui; Timothy Li; Lijia Chen; Lawrence Iu; Marten Brelen; Alvin L Young
Journal:  Int Ophthalmol       Date:  2021-05-26       Impact factor: 2.031

2.  Ocular Tuberculosis.

Authors:  Julian A Marin-Acevedo; Razvan M Chirila; Jennifer B Cowart
Journal:  J Gen Intern Med       Date:  2019-07-24       Impact factor: 5.128

3.  Splenic tuberculosis and multifocal serpiginoid choroiditis.

Authors:  Pradeep Kumar; Prateek Kakkar; Raghav Ravani; R Karthikeya; Atul Kumar
Journal:  Int Ophthalmol       Date:  2017-08-10       Impact factor: 2.031

4.  Could different aqueous humor and plasma cytokine profiles help differentiate between ocular sarcoidosis and ocular tuberculosis?

Authors:  L De Simone; M Bonacini; S Croci; L Cimino; R Aldigeri; F Alessandrello; V Mastrofilippo; F Gozzi; E Bolletta; C Adani; A Zerbini; G M Cavallini; L Fontana; C Salvarani
Journal:  Inflamm Res       Date:  2022-06-28       Impact factor: 6.986

5.  Clinical Features and Outcomes of Patients With Tubercular Uveitis Treated With Antitubercular Therapy in the Collaborative Ocular Tuberculosis Study (COTS)-1.

Authors:  Rupesh Agrawal; Dinesh Visva Gunasekeran; Robert Grant; Aniruddha Agarwal; Onn Min Kon; Quan Dong Nguyen; Carlos Pavesio; Vishali Gupta
Journal:  JAMA Ophthalmol       Date:  2017-12-01       Impact factor: 7.389

6.  Early treatment of tuberculous uveitis improves visual outcome: a 10-year cohort study.

Authors:  Luis Anibarro; Eliana Cortés; Ana Chouza; Alberto Parafita-Fernández; Juan Carlos García; Alberto Pena; Carlos Fernández-Cid; África González-Fernández
Journal:  Infection       Date:  2018-06-04       Impact factor: 3.553

7.  Review of people with retinal vasculitis and positive QuantiFERON®-TB Gold test in an area nonendemic for tuberculosis.

Authors:  David R Brunner; Sandrine A Zweifel; Daniel Barthelmes; Fabio Meier; Christian Böni
Journal:  Int Ophthalmol       Date:  2017-10-13       Impact factor: 2.031

Review 8.  Infectious uveitis: an Asian perspective.

Authors:  Aniruddha Agarwal; Kanika Aggarwal; Vishali Gupta
Journal:  Eye (Lond)       Date:  2018-10-12       Impact factor: 3.775

Review 9.  Systemic diseases and the cornea.

Authors:  Ruchi Shah; Cynthia Amador; Kati Tormanen; Sean Ghiam; Mehrnoosh Saghizadeh; Vaithi Arumugaswami; Ashok Kumar; Andrei A Kramerov; Alexander V Ljubimov
Journal:  Exp Eye Res       Date:  2021-01-21       Impact factor: 3.467

10.  Anti-TB monotherapy for choroidal tuberculoma: an observational study.

Authors:  Ashish Khalsa; Anup Kelgaonkar; Soumyava Basu
Journal:  Eye (Lond)       Date:  2021-04-01       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.